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Abstract
Background: Graves’ disease (GD) is the leading cause of hyperthyroidism and thyroid eye disease inherited as a complex
trait. Although geoepidemiology studies showed relatively higher prevalence of GD in Asians than in Caucasians, previous
genetic studies were contradictory concerning whether and/or which human leukocyte antigen (HLA) alleles are associated
with GD in Asians.
Methodology/Principal Findings: We conducted a case-control association study (499 unrelated GD cases and 504
controls) and a replication in an independent family sample (419 GD individuals and their 282 relatives in 165 families). To
minimize genetic and phenotypic heterogeneity, we included only ethnic Chinese Han population in Taiwan and excluded
subjects with hypothyroidism. We performed direct and comprehensive genotyping of six classical HLA loci (HLA-A, -B, -C,
-DPB1, -DQB1 and -DRB1) to 4-digit resolution. Combining the data of two sample populations, we found that B*46:01 (odds
ratio under dominant model [OR] =1.33, Bonferroni corrected combined P [PBc] =1.17610
22), DPB1*05:01 (OR =2.34,
PBc=2.58610
210), DQB1*03:02 (OR =0.62, PBc =1.97610
22), DRB1*15:01 (OR =1.68, PBc=1.22610
22)a n dDRB1*16:02 (OR =
2.63, PBc =1.46610
25) were associated with GD. HLA-DPB1*05:01 is the major gene of GD in our population and singly
accounts for 48.4% of population-attributable risk.
Conclusions/Significance: These GD-associated alleles we identified in ethnic Chinese Hans, and those identified in other
Asian studies, are totally distinct from the known associated alleles in Caucasians. Identification of population-specific
association alleles is the critical first step for individualized medicine. Furthermore, comparison between different
susceptibility/protective alleles across populations could facilitate generation of novel hypothesis about GD pathophys-
iology and indicate a new direction for future investigation.
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Introduction
Graves disease (GD, [MIM 27500], http://www.ncbi.nlm.nih.
gov/Omim/) is the leading cause of hyperthyroidism and thyroid
eye disease, manifested with diffuse goiter, hyperthyroidism,
thyroid-specific auto-antibodies, with/without ophthalmopathy
and/or dermopathy [1]. Its prevalence in general population is
around 1.0–1.6%, more common in females [2,3]. The etiology of
GD is multifactorial, with considerable genetic influence [1],
evidenced by family clustering (lsister between 8 and 15) [4] and a
higher concordance rate in monozygotic twins (0.35) than in
dizygotic twins (0.03) [5]. The genetic contribution to GD was
estimated as high as 79% [5]. Although geoepidemiology studies
show relatively higher prevalence of GD in Asians than in
Caucasians [6], whether/what genetic factors are important for
GD in Asians is not yet clear [7–9].
As an autoimmune disorder, the pathogenesis of GD remains
elusive. Among all the methods for studying diseases pathophys-
iology, genetic approach has valuable capability as being both
hypothesis-testing and hypothesis-generating. Linkage analysis for
GD, although yielded inconsistent results across studies [8,10–14],
did demonstrate that the HLA region is linked to GD susceptibility
in both Caucasian and Chinese Han populations according to
others’ [10] and our [13] studies. Association studies have been
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CTLA4, PTPN22, CD40, FCRL3, CD25, TG and TSHR
[8,9,15,16]. Although the HLA loci were most promising, the risk
alleles identified in Caucasians (such as the HLA-DRB1*03, C*03,
C*07, C*16 and the DRB1*03-DQB1*02-DQA1*05:01 haplotype)
[7,8,11,17] showed no associations in Asians. (It is noteworthy that
throughout this manuscript we have adapted the new HLA
nomenclature system [18], which was mandated to become
effective since April 2010.) Instead, in studies conducted in
Chinese, Japanese, Koreans and Thai, GD was reported to
associate with other class I or class II alleles [8,11,19–32]
(Supplemental Table S1). There has been no conclusion regarding
which HLA alleles are associated with GD in Asians [11,15]. The
reports from previous studies were contradictory, at least partly
because of issues related to sample sizes, sample heterogeneity
(both in ethnic background and phenotype), population stratifica-
tion, genotyping resolution, and extent of coverage. Direct HLA
allele genotyping (instead of using nearby SNPs as surrogates) is
very expensive and requires special techniques, which might
explain why most previous studies only could afford small sample
sizes and limited extent of coverage.
In this study, we conducted a case-control association study (499
unrelated GD cases and 504 controls) by direct and comprehen-
sive genotyping of 6 classical HLA loci (HLA-A, -B, -C, -DPB1,
-DQB1 and -DRB1) to 4-digit resolution. For replication, we used
an independent cohort of family samples (419 GD individuals and
their 282 relatives in 165 extended families) genotyped with a
different platform with the same 6-locus coverage and 4-digit
resolution. We also managed to reduce heterogeneity in genetic
background by including only ethnic Chinese Han individuals,
and in disease phenotype (in our family samples) by excluding
subjects with family history of hypothyroidism [13]. In contrast to
the known associated HLA alleles in Caucasians, we found a whole
distinct spectrum of associated alleles.
Results
HLA association tests using unrelated GD cases and
controls
In the case-control association study, we observed a total of 196
HLA alleles from 6 loci (minimum: 18 alleles from HLA-DQB1,
maximum: 60 alleles from HLA-B) (Supplemental Table S2).
Because of limited power to detect association with rare alleles, we
only tested for disease association with common alleles (with a
frequency higher than 5% in either cases or controls) (HLA-A:6
alleles; HLA-B: 4 alleles; HLA-C: 5 alleles; HLA-DPB1: 4 alleles;
HLA-DQB1: 7 alleles and HLA-DRB1: 8 alleles). For the results to
be robust, we reported Bonferroni corrected P values as our main
results in the text as well as in the Tables. However, for the
purpose of comprehensiveness, we also kept some nominal P
values in certain columns of the Tables. (Please see the ‘‘Statistical
analysis’’ section in ‘‘Materials and Methods’’ for details.) Of these
34 alleles tested, we found 8 alleles showing frequency difference
with nominal P values smaller than 0.05 in the Armitage trend test,
as well as in allelic test and in association test under dominant-
model. However, only 4 of the 8 alleles were statistically significant
after Bonferroni correction (DPB1*05:01, odds ratio under
dominant model [OR] =2.34, Bonferroni-corrected P=1.66
10
26; DQB1*05:02, OR =2.34, Bonferroni-corrected P=
1.5610
24; DRB1*12:02, OR =0.51, Bonferroni-corrected P=1.7 6
10
22; DRB1*16:02, OR =2.63, Bonferroni-corrected P=5.4 610
26)
(Table 1). Both susceptibility alleles and protective alleles were
found. It is noteworthy that the alleles associated with GD in
Caucasians showed either no evidence of association (DRB1*03,
DQB1*02, C*07 and C*03) or were not observed in our samples
(C*16) (Supplemental Table S3 and Table S4). DQA1*05:01,a n o t h e r
allele on the risk haplotype (DRB1*03:01-DQA1*05:01-DQB1*02)i n
Caucasians, was not genotyped in our study. However, in Asians,
DQA1*05:01 is not known to have noticeable linkage disequilibrium
with any of the susceptibility alleles we reported [33].
Replication using the family-based study and other
supporting evidence from previous association reports in
Asians
We next tested the familial cohort for replication using a
different genotyping platform. The comprehensive FBAT P values
were summarized in Table 2 and Supplemental Table S4. We
then calculated the Bonfferoni corrected P values of our combined
case-control and family-based analysis. We found that B*46:01
(odds ratio under dominant model [OR] =1.33, Bonferroni
corrected combined P [PBc] =1.17610
22), DPB1*05:01 (OR =
2.34, PBc=2.58610
210), DQB1*03:02 (OR =0.62, PBc=
1.97610
22), DQB1*05:02 (OR =1.89, PBc=1.60610
23),
DRB1*15:01 (OR =1.68, PBc=1.22610
22) and DRB1*16:02
(OR =2.63, PBc=1.46610
25) were associated with GD. Review
of GD association studies previously conducted in Asian
populations revealed that 4 (B*46:01, DPB1*05:01, DQB1*05:02
Table 1. Association results (from 499 Graves’ disease cases and 504 controls) of the four alleles with Bonferroni corrected P value
smaller than 0.05.
HLA allele
Allele Frequency
(cases vs. controls)
Allelic test
a
(nominal
P value)
Genotypic test
a
(nominal
P value)
Armitage trend
test
a (nominal
P value)
Dominant model
a
(nominal
P value)
Dominant model
a
(Bonferroni corrected
P value)
DPB1*05:01 52.6% vs. 43.5% OR =1.44
P=1.0610
24
3.0610
27 1.0610
26 OR =2.34
P=4.7610
28
P=1.6610
26
DQB1*05:02 16.3% vs. 9.3% OR =1.89
P=2.9610
26
3.0610
25 1.0610
25 OR =2.00
P=4.3610
26
P=1.5610
24
DRB1*12:02 4.7% vs. 8.6% OR =0.53
P=5.6610
24
1.1610
23 5.6610
24 OR =0.51
P=4.9610
24
P=1.7610
22
DRB1*16:02 10.9% vs. 4.8% OR =2.43
P=3.5610
27
8.9610
27 1.9610
27 OR =2.63
P=1.6610
27
P=5.4610
26
aAll P values (except for those in the last column) reported were nominal P values. The study-wide significance cut-off nominal P value should be 0.00147 (=0.05/34,
which is the Bonferroni correction for a total of 34 tested alleles). The statistically significance level for Bonferroni corrected P value (reported in the last column) should
be 0.05. OR, odds ratio.
doi:10.1371/journal.pone.0016635.t001
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least two studies, and one allele (DRB1*12:02) (, which showed
protective effect in our case-control study but was unable to be
replicated in our family-based study), was reported as a protective
allele previously (Supplemental Table S1). Again, neither our
family-based association study nor the literature review showed
supports for alleles associated in Caucasian populations (Supple-
mental Table S1 and Table S4).
Dissection of individual effect of each associated allele
It is well known that there are certain extended haplotypes
across classical HLA loci [33]. In order to know if some of the
observed associations represented the same association signal
caused by linkage disequilibrium (LD), we therefore analyzed the
LD between these 7 alleles (of 4 loci) with association signals
(B*46:01 of the HLA-B locus; DRB1*12:02, DRB1*15:01 and
DRB1*16:02 of the HLA-DRB1 locus; DQB1*03:02 and
DQB1*05:02 of the HLA-DQB1 locus; DPB1*05:01 of the HLA-
DPB1 locus). The pairwise r
2 values of almost all allele pairs were
,0.02 (Figure 1), indicating that most of the association signals
were independent from each other. The only exception was the
LD between DQB1*05:02 and DRB1*16:02 (cases: r
2=0.62;
controls: r
2=0.48) (Figure 1). Further analysis showed that all
DRB1*16:02 alleles were on the DQB1*05:02-DRB1*16:02
haplotype, and the haplotype frequency was 4.77% in controls
and 10.89% in GD cases (P=3.50610
27). On the other hand,
those chromosomes containing DQB1*05:02 but not carrying this
haplotype showed similar frequencies in controls (4.57%) and cases
(5.44%) (P=0.383). Therefore, the observed association of
DQB1*05:02 is secondary to its LD with DRB1*16:02, and by
itself DQB1*05:02 did not confer independent susceptibility.
HLA-DPB1*05:01 confers susceptibility through a
dominant mode of effect
It is not clear previously whether HLA alleles confer
susceptibility/protective effect to GD through a dominant,
additive or recessive mode. We found that the subjects with one
DPB1*05:01 allele (OR =2.37, 95% confidence interval [CI] =
1.72–3.62) and those with two alleles (OR =2.25, CI =1.51–
3.34) had similar OR compared to the individuals with zero allele,
suggesting that HLA-DPB1*05:01 confers susceptibility through a
dominant mode of inheritance (Table 3). For other alleles, the
allele frequencies were not high enough for us to perform similar
analyses. It is noteworthy that DPB1*05:01 showed deviation from
Hardy-Weinberg (HW) equilibrium in GD cases (P=1.6610
210)
but not in controls (P=0.14) (Table 3). There were more
heterozygotes in the unrelated GD cases than expected under
HW equilibrium, which is compatible with the dominant mode.
The DPB1*05:01 genotypes from the family sample also showed
similar HW disequilibrium pattern with increased heterozygotes in
probands (P=0.0059), but not in family founders (P=0.67)
(Table 3).
Sizeable population-attributable risk percentage of these
HLA alleles
These HLA alleles conferred sizeable population-attributable
risk percentage (PAR%) for GD (Table 4). DPB1*05:01 singly
accounts for 48.4% of population-attributable risk. We built a
logistic regression model for Chinese Han population in Taiwan
based on the data of these 6 alleles and gender, and the area under
curve of the receiver operating characteristic (ROC) curve was
0.75 (Figure 2). Examining the PAR% (Table 4) and logistic
regression models (data not shown) further supported that the
association signal from DQB1*05:02 was due to its LD with
DRB1*16:02.
Discussion
Association analysis is powerful for genetic mapping, but has
been criticized for frequent spurious signals resulted from
population stratification. The ways to ensure more robust results
include using family-based samples and/or getting independent
replications. Herein we report convincing data using both ways.
Before our study, HLA-B*46 might be the only HLA allele
associated with GD with good replications in Asians [8,11,19]. In
this study, we establish the paramount role of one allele (HLA-
Table 2. Replication with our family-based study and/or previous studies in Asians.
HLA allele
Case-control study
under dominant
model (nominal P
value)
Family-based study
under dominant
model
(nominal P value)
Combined P value
(nominal P value)
Combined P value
(Bonferroni
corrected P value)
Positive results in previous studies in
Asian populations
a
B*46:01 4.9610
22 5.5610
23 3.4610
24 1.2610
22 Chan et al. 1978 [20]; Hawkins et al, 1985 [21];
Yeo et al. 1989 [22]; Dong et al. 1992 [23];
Inoue et al. 1992 [24]; Onuma et al. 1994 [25];
Caven et al. 1994 [26]; Huang et al. 2003 [19];
Park et al. 2005 [27]
DPB1*05:01 4.7610
28 7.3610
25 7.6610
212 2.6610
210 Dong et al. 1992 [23]; Onuma et al. 1994 [25];
Takahashi et al. 2006 [28].
DQB1*03:02 8.9610
23 (Pro)
b 4.7610
22 (Pro) 5.8610
24 (Pro) 2.0610
22 Nil
DQB1*05:02
c 4.3610
26 8.0610
21 (Pro) 4.7610
25 1.6610
23 Park et al. 2005 [27]; Wongsurawat et al. 2006
[29]
DRB1*15:01 2.8610
23 4.9610
22 3.6610
24 1.2610
22 Nil
DRB1*16:02 1.6610
27 6.5610
21 4.3610
27 1.5610
25 Park et al. 2005 [27]; Wongsurawat et al. 2006
[29]
aThe more detailed summary of previous Asian HLA-GD association studies can be found in Supplemental Table S1.
bThe annotation ‘‘(Pro)’’ indicates ‘‘protective’’ effect.
cAlthough DQB1*05:02 got association signals from multiple independent studies, we consider these association signals were caused by the linkage disequilibrium
between DQB1*05:02 and DRB1*16:02. Please see the main texts for detailed analyses.
doi:10.1371/journal.pone.0016635.t002
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and DRB1*15:01), provide convincing replications of other three
alleles (B*46:01, DRB1*12:02 and DRB1*16:02), and exclude
independent effect of one allele (DQB1*05:02). We consider these
6 alleles to be genuine susceptibility/protective HLA alleles in
our ethnic Chinese population, and probably in other Asian
populations.
A recent geoepidemiology review [6] demonstrated that, unlike
other autoimmune diseases (such as type 1 diabetes, multiple
sclerosis and inflammatory bowel disease) which in general have
higher prevalence in Caucasians, Graves’ disease seems to have
slightly higher prevalence in Asians. Be the relatively high
prevalence of GD caused by genetic factors or environmental
factors (or the interplay of both) is still an open question. However,
the well-established HLA risk alleles of GD in Caucasians (HLA-
DRB1*03, C*03, C*07, C*16) have either low or extremely low
allele frequencies in Asians [33,34]. The risk allele of PTPN22,a
major autoimmune susceptibility gene of GD and several other
Table 3. Analysis of DPB1*05:01 genotype distribution and odds ratio.
X/X
a 05:01/X
a 05:01/05:01
a
Hardy-Weinberg equilibrium
test
Founders
(Family samples)
66 (23.1%)
b 146 (51.2%) 73 (25.6%) P=0.67
Probands
(Family samples)
24 (14.5%) 99 (60.0%) 42 (25.5%) P=5.9610
23
Controls
(Unrelated samples)
151 (30.0%) 264 (52.5%) 88 (17.5%) P=0.14
Cases
(Unrelated samples)
77 (15.5%) 319 (64.2%) 101 (20.3%) P=1.6610
210
Odds ratio
c
(X/X as reference)
Reference 2.37
CI (1.72–3.26)
2.25
CI (1.51–3.34)
Odds ratio
(X/0501 as reference)
0.42
CI (0.31–0.58)
Reference 0.95
CI (0.68–1.32)
a‘‘X’’ indicates ‘‘any DPB1 allele except for DPB1*05:01’’. Therefore X/X means zero DPB1*05:01 allele, 05:01/X means one DPB1*05:01 allele and 05:01/05:01 means two
DPB1*05:01 alleles.
bFor DPB1*05:01 genotype distribution of 4 different groups of individuals (4 different rows), each cell is presented as count of individuals of that specific genotype
followed by the row percentage (inside the parenthesis).
cOdds ratio is calculated based on unrelated cases and unrelated controls. CI, 95% confidence interval.
doi:10.1371/journal.pone.0016635.t003
Figure 1. Linkage disequilibrium analysis of HLA-B, HLA-DRB1, HLA-DQB1 and HLA-DPB1 alleles showing significant associations with
GD. The distances between consecutive loci are approximately 1225 Kb, 81 kb and 416 Kb respectively. The r
2 value (6100) of any allele pair was
plotted inside the corresponding cell. Except for strong linkage disequilibrium (r
2=0.48 in controls, r
2=0.62 in cases) between DRB1*16:02 and
DQB1*05:02, in general the r
2 value between other alleles was quite low.
doi:10.1371/journal.pone.0016635.g001
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[35,36]. Therefore, it is obvious that the genetic landscapes of GD
in Asians and in Caucasians are quite different. However, even
after decades of research, the major susceptibility/protective genes
of GD in Asians were still unclear. Our current study establishes
the major role of HLA-DPB1*05:01 (PAR% =48.4%), discovers
two novel associated HLA alleles, and confirms three other HLA
alleles. We believe that, after our current work and a careful
comprehensive review of earlier GD association studies in Asians,
the missing genetic ‘‘dark matter’’ in Asians is beginning to be
observed.
Not all of the associated alleles in our case-control study were
replicated in our family-based association test. Admittedly, the
sample size of our family collection, although among the largest
GD family collections worldwide, was still not big enough to
always detect genuine association alleles with moderate effect sizes.
Furthermore, due to the stochastic nature of sample collection in
association study, any two independent studies (even with the same
theoretical statistical power) may not detect the same association
signals. In this current manuscript, for those alleles that could not
be directly replicated in our family-based association test, at least
the directions of effects were the same (both susceptible or both
protective in our case-control study and family-based study)
Figure 2. Receiver operating characteristics (ROC) curve for the logistic regression model. Disease = 23.6802+0.44876B*46:01+
0.88836DPB1*05:01 – 0.34946DQB1*03:02 –0 . 4 9 2 6DRB1*12:02+0.83886DRB1*15:01+1.07276DRB1*16:02+1.58656Female. The logistic
regression model was built based on the data from our unrelated case-control study individuals. Genotypes were coded following a dominant
inheritance mode. The area under curve (AUC) of this ROC curve is 0.75.
doi:10.1371/journal.pone.0016635.g002
Table 4. Population-attributable risk percentage of seven
associated alleles and one haplotype under dominant model.
HLA allele or haplotype
Frequency of
(AA + Aa)
a Odds ratio
b PAR%
c
B*46:01 25.2% 1.33 7.7%
DPB1*05:01 70.0% 2.34 48.4%
DQB1*03:02 17.3% 0.62 27.1%
DRB1*12:02 16.7% 0.51 28.9%
DRB1*15:01 12.9% 1.68 8.1%
DRB1*16:02
d 9.3% 2.63 13.3%
DQB1*05:02-DRB1*16:02
d 9.3% 2.65 13.3%
DQB1*05:02
d 17.9% 2.01 15.3%
aHomozygotes or heterozygotes for the specific allele of interest. This kind of
coding is to test PAR% under dominant model.
bOdds ratio under dominant model.
cPAR% would be a negative value when the allele is protective.
dThe PAR% values of DQB1*05:02, DRB1*16:02 and the DQB1*05:02-DRB1*16:02
haplotype are very similar. A single susceptibility allele (most likely DRB1*16:02,
please see the main text for details) is responsible for the risk, and therefore
these three PAR% should only be counted once.
doi:10.1371/journal.pone.0016635.t004
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found (also with the same directions of effects) (Table 2). The
ultimate proof will rely on future association studies and/or
functional assays.
Direct genotyping of classical HLA alleles (instead of using nearby
SNPs as surrogates) is expensive and requires special techniques.
Considering the aspects of sample size, genotyping resolution and loci
coverage, to our knowledge this current study has hitherto been the
most ambitious design worldwide for HLA association study with
GD. While the advantages of big sample size and good genotyping
resolution are self-evident, the importance of comprehensive loci
coverage can not be over-emphasized. Possible linkage disequilibrium
between HLA loci has been a thorny issue when researchers tried to
identify the genuine locus responsible for the association signal
[11,15,17]. We consider it crucial to examine as many classical HLA
lociaspossiblein asinglestudy,whichmayprovideanopportunityto
delineate the contribution of each locus. In this study, we genotyped 6
classical HLA loci (HLA-A, -B, -C, -DPB1, -DQB1 and -DRB1)f o ra l l
participants, a design rarely found in previous HLA-GD association
studies in Asians (Supplemental Table S1) or in Caucasians [11,15].
B e c a u s eo ft h ec o m p r e h e n s i v el o c u sc o v e r a g e ,w eu n c o v e r e dt h a tt h e
association signal from HLA-DQB1*05:02 was secondary to its LD
with HLA-DRB1*16:02. After careful analysis, we reported 6
susceptibility/protective alleles, each of them representing indepen-
dent association signals. We did not include DQA1or DRB3,4,5 inthis
study, partly because of the unavailability of genotyping kits and
partly because that their LD with corresponding DQB1 or DRB1
alleles would be too tight to be delineated.
DPB1*05:01 has a large effect size (OR =2.34, under dominant
model) and a very high PAR% (48.4%) in our study. It is curious
why the association of DPB1*05:01 has not been addressed earlier.
The association of DPB1*05:01 and GD has not been detected in
Caucasians, probably because of low allele frequency (mostly ,5%
in Caucasians) (Figure 3) [33,34]. In Asians, the whole HLA-DPB1
locus was simply overlooked for more than a decade. In 1992 and
1994, three published studies [23–25] covered the HLA-DPB1
locus in their study design, and actually two (Dong et al. [23] and
Onuma et al. [25]) of the three reported DPB1*05:01 as a
susceptibility allele. However, none of later studies incorporated
the HLA-DPB1 locus for association tests, with the only exception
that in 2006 Takahashi et al. [28] (from the same research team as
the Dong et al. [23] paper) reported their results (Table 1 and
Supplemental Table S1). This again justifies our approach to insist
on comprehensive loci coverage across the whole HLA region
instead of only focusing on certain ‘‘promising’’ loci. Although
having been overlooked in the GD research field for more than a
decade, HLA-DPB1*05:01 was shown to be associated with several
other immune-related phenotypes/diseases such as multiple
sclerosis [37], primary biliary cirrhosis [38] and chronic hepatitis
B infection [39], which, to some degree, supports that DPB1*05:01
is an HLA allele with pertinent biological significance.
It has not escaped our notice that of the four susceptibility alleles
reported in this current GD study, two are well-known
susceptibility alleles of multiple sclerosis (MS) (DRB1*15:01 of
the conventional MS worldwide [40] and DPB1*05:01 of the
opticospinal MS in Asians [37]). Some (but not all) previous studies
[41] supported that GD and MS might co-occur at greater than
expected rates within proband patients or their families. It would
be intriguing to explore if there are common pathogenesis
pathways between these two diseases.
It seems to be counterintuitive that the spectra of susceptibility/
protective HLA alleles of GD are completely different between
Caucasians and Asians. The main reason for this probably is the
difference in allele frequencies. The most prominent susceptibility
allele in Caucasians, DRB1*03:01, has a much lower frequency in
Asians, ranging from ,3% in Japanese and Koreans to 4–9% in
Chinese (Figure 3) [33,34] while of the six alleles we report here,
four (B*46:01, DPB1*05:01, DRB1*12:02 and DRB1*16:02) have
very low frequencies in Caucasians (Figure 3) [33,34]. There have
been several examples that certain susceptibility/protective alleles
of genes for other autoimmune diseases varied in frequencies
across populations [36,37].
Genetic study, aside from testing existed hypothesis, has a
special capability of generating new hypothesis. Difference of
susceptibility/protective alleles across populations provides a great
opportunity for investigating the mechanism how HLA molecules
get involved in GD pathogenesis. At least partly inspired by the
successful examples of the ‘‘shared epitope hypothesis’’ for
pathogenesis of rheumatoid arthritis or type 1 diabetes mellitus
[36,42,43], it has been postulated that arginine at position 74 of
the HLA-DRB1 chain is critical for GD pathogenesis [44], mostly
based on the association findings from studies conducted in
Caucasians. However, the residues at position 74 of DRB1*15:01
and DRB1*16:02 reported in our association study are both
alanine [45], which is the common residue at this position
considered to be neutral for GD risk [44]. Further we also found
susceptibility/protective alleles at class I loci, and other class II
alleles. Accounting for all available evidence, we propose that the
HLA region critical for GD pathogenesis is not only limited to
position 74 of the DRB1 molecule. We did not find a single
sequence ‘‘signature’’ which can explain all the associated HLA
alleles identified in Caucasians and Asians. Comparison of the 3-D
structure of various associated alleles and careful examination of
joint effect of more than one HLA molecules might provide better
hints for future study.
In summary, we report the results of our case-control and
family-based GD-HLA association tests, with some strong
supporting evidence from previous studies in Asians. The
associated alleles are quite different from those discovered in
Caucasians. HLA-DPB1*05:01 is the major gene of GD in our
population, and a total of 6 susceptibility/protective alleles
account for sizeable population-attributable risk. Identification of
population-specific association alleles is the critical first step for
individualized medicine. Furthermore, comparison between dif-
ferent susceptibility/protective alleles across populations could
facilitate generation of novel hypothesis about GD pathophysiol-
ogy and indicate a new direction for future investigation.
Materials and Methods
Ethics statement
The study was approved by the Institutional Review Board of
National Taiwan University Hospital. Written informed consent
was obtained from all GD patients and their relatives who
participated in this project. The population-based unrelated
controls were from the ‘‘Han Chinese Cell and Genome Bank in
Taiwan’’ [46].
Participant enrollment and diagnosis
The diagnosis of GD was made based on the presence of
biochemical hyperthyroidism together with either the presence of
thyroid eye disease or a diffuse goiter and a significant titer of auto-
antibodies (including anti-microsomal, anti-thyroglobulin or anti-
TSH receptor antibody) as previously reported [13]. To enrich
phenotypic homogeneity, (in our family collection,) families having
any family member with known possible Hashimoto’s thyroiditis
([MIM603372]) were not included. Furthermore, only subjects
whose four grandparents were of Chinese Han origin were
Major and Novel Associations between GD and HLA
PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e16635Figure 3. Allele frequency variations of HLA-DPB1*05:01 and HLA-DRB1*03:01 across worldwide populations. The allele frequencies
(6100%) are presented with different colors, shown as the color bar below the figure. (A) HLA-DPB1*05:01, the major GD susceptibility allele we
demonstrated, is much more prevalent in Asians than in Caucasians. (B) HLA-DRB1*03:01, the major GD susceptibility allele in Caucasians, has low
frequencies in Asians. The data were screenshots from New Allele Frequency Database: http://www.allelefrequencies.net [33] with permission.
doi:10.1371/journal.pone.0016635.g003
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GD patients were recruited from individuals attending the
outpatient clinic of National Taiwan University Hospital or
affiliated Far Eastern Polyclinics. Pedigrees were ascertained
through a GD proband. All the individuals enrolled in this study
were interviewed and assessed by board-certified endocrinologists.
The population-based unrelated controls were from the ‘‘Han
Chinese Cell and Genome Bank in Taiwan’’ [46]. As in other GD
studies, our unrelated cases showed a higher proportion of females
(82.2%) than males. The average age of unrelated GD cases was
41.9 years (s.d.=12.4 years), and of unrelated controls was 55.7
years (s.d. =18.5 years).
Genotyping
For samples in our case-control study, we determined HLA-A,
-B, -C, -DQB1 and -DRB1 genotypes using the Dynal RELI SSO
typing kits (Dynal biotech Ltd, Bromborough, Wirral, U.K., now
part of Life Technologies, Carlsbad, CA, USA) (http://www.
invitrogen.com/) according to manufacturer’s instructions. Briefly,
polymerase chain reactions (PCR) using locus-specific primer sets
were applied to amplify both exon 2 and exon 3 of class I (HLA-A,
-B and -C) genes or exon 2 of class II (-DQB1 and -DRB1) genes.
Subsequently, PCR products were hybridized with sequence-
specific oligonucleotide (SSO) probes previously fixed in a linear
array on a nylon membrane (HLA-A: 48 probes, -B: 61 probes, -C:
37 probes, -DQB1: 41 probes and -DRB1: 60 probes). We then
interpreted the genotypes using the Pattern Matching program
(Dynal biotech Ltd). Due to the lack of DPB1 genotyping kit in the
Dynal RELI SSO system, we genotyped HLA-DPB1 based on a
sequence-specific primer (SSP) amplification method using ‘‘Gold
SSP HLA-DPB1 High resolution Kit’’ (Invitrogen Corp., now part
of Life Technologies, Carlsbad, CA, USA) (http://www.invitrogen.
com) according the manufacturer’s protocol. Briefly, forty-eight
PCR reactions were performed for each DNA sample. After PCR
amplification and electrophoresis, the patterns of positive amplifi-
cations were used to interpret HLA-DPB1 genotypes with the
company’s UniMatch software (Invitrogen Corp.).
For samples in our family-based study, we performed
genotyping for all these 6 HLA loci using a different platform,
the LABType SSO kit (One lambda Inc., Canoga Park, CA, USA)
(http://www.onelambda.com/), in order to prevent potential
spurious association caused by the same platform-related geno-
typing error. Briefly, PCR products were hybridized with probes
bound to fluorescently coded micro-spheres (HLA-A: 58/61/63
probes, -B: 100 probes, -C: 56 probes, -DPB1: 40 probes, -DQB1:
37 probes and -DRB1: 70 probes). Subsequently, a flow analyzer
was used to identify the fluorescent intensity on each micro-sphere
(LABType visual software; One lambda Inc.) and assignment of
HLA genotype was obtained based on the reaction pattern.
Ambiguity, which refers to the same reaction patterns produced
by several genotype combinations [47], was dealt with by assigning
allele genotypes according to common alleles (allele frequency
.0.01) found in Taiwanese population [48] and southern Chinese
populations [33,34] as determined in the population studies of the
13
th international histocompatibility workshop.
Statistical analysis
At any HLA loci, there are multiple alleles. We followed the
common practice of most HLA association studies and coded
tested alleles in a 2-allele format. For example, when we
performed statistic tests for HLA-B*46:01, the allele was either
coded as ‘‘HLA-B*46:01’’ or ‘‘X’’ (which meant any other possible
alleles at the HLA-B locus). Consequently, in this example, the
genotype of an individual would be coded as one of the three:
B*46:01/B*46:01, B*46:01/X or X/X.
For the case-control study (499 unrelated GD cases and 504
unrelated controls), we tested each of the 34 common HLA alleles
(with allele frequency greater than 5%) with 1-degree-of-freedom
(d.f.) allelic test, 2-d.f. genotypic test, 1-d.f. Cochran-Armitage
trend test, 1-d.f. dominant logistic regression model and 1-d.f.
gender-adjusted dominant logistic regression model, using PLINK
[49] v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) or SAS
v9.2 (http://www.sas.com). For completeness, we calculated both
nominal P values and Bonferroni corrected P values. Considering
that 34 alleles were tested, regardless of possible linkage
disequilibrium between certain alleles, the most conservative
study-wide significance cut-off nominal P value for Bonferroni
correction should be 0.0015 (=0.05/34). For all of our main
results, we reported Bonferroni corrected P values, which were
nominal P values multiplied by 34, the number of measures being
tested [50,51]. Bonferroni corrected P values smaller than 0.05
were considered statistically significant [50,51].
For the results to be robust, we reported Bonferroni corrected P
values as our main results in the text as well as in the Tables.
However, for the purpose of comprehensiveness, we also kept
some nominal P values in certain columns of the Tables.
Forthe familystudy(419 GDcasesandtheir282familymembers
in 165 extended pedigrees), we applied PedCheck v1.1 to check for
genotyping error under the known family structure. We then used
family-based association test [52] (FBAT) v1.7.3 (http://www.
biostat.harvard.edu/,fbat/default.html) for association analyses. A
dominant model was chosen based on our observation that HLA
alleles (at least DPB1*05:01 shown in our analysis) might exert the
effect in a dominant mode. We applied the ‘‘-e’’ option in FBAT to
produce the empirical variance and make the test robust to the
presence of linkage [52].
We calculated combined P values (combination of our case-
control study and our family-based association test) based on the
method described by de Bakker et al. [53]. Briefly, z statistics were
calculated based on the individual original P values, then summed
up after considering the effect direction and weighting, and then
converted back to get the combined P value. Appropriate
weighting and effective sample sizes were derived from PBAT
[54] and Genetic Power Calculator [55] based on the allele
frequency and OR of the controls and family founders [53]. Again,
nominal P values smaller than 0.0015 or Bonferroni corrected P
values smaller than 0.05 were considered statistically significant.
We analyzed the linkage disequilibrium (LD) patterns between
those 7 alleles with association signals (B*46:01 of the HLA-B
locus; DRB1*12:02, DRB1*15:01 and DRB1*16:02 of the HLA-
DRB1 locus; DQB1*03:02 and DQB1*05:02 of the HLA-DQB1
locus; DPB1*05:01 of the HLA-DPB1 locus) using HaploView v4.1
(http://www.broadinstitute.org/haploview/haploview) and the
SAS HAPLOTYPE procedure. By definition, LD is a measure-
ment between alleles at different loci (for example, between
B*46:01 and DRB1*12:02); therefore we did not try to find if
alleles of the same locus (for example, DRB1*12:02 and
DRB1*15:01) co-existed too often or too rarely.
We estimated the population attributable risk percentage
(PAR%) for the susceptibility/protective genotypes using the
formula [56]:
PAR%~ Pe| RR{1 ðÞ ½  = Pe| RR{1 ðÞ ½  z1 fg
where Pe represents the susceptibility/protective genotype fre-
quency (coded as the dominant-model) in the population, and RR
represents relative risk of the risk genotype. Given the relatively
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on the genotype frequencies in healthy controls, and RR can be
approximated by OR of the risk genotypes [56].
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